IDH1
Basic information
Region (hg38): 2:208236229-208266074
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- Transitional cell carcinoma of the bladder (1 variants)
- not provided (1 variants)
- Multiple myeloma (1 variants)
- Glioblastoma (1 variants)
- Hepatocellular carcinoma (1 variants)
- Lung adenocarcinoma (1 variants)
- Prostate adenocarcinoma (1 variants)
- Myelodysplastic syndrome (1 variants)
- Neoplasm of brain (1 variants)
- Medulloblastoma (1 variants)
- Neoplasm of the large intestine (1 variants)
- Acute myeloid leukemia (1 variants)
- Brainstem glioma (1 variants)
- Astrocytoma (1 variants)
- Adenoid cystic carcinoma (1 variants)
- Malignant melanoma of skin (1 variants)
- Breast neoplasm (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IDH1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 141 | 142 | ||||
missense | 231 | 244 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 3 | 4 | 7 | |||
non coding | 13 | 13 | ||||
Total | 1 | 4 | 231 | 146 | 17 |
Variants in IDH1
This is a list of pathogenic ClinVar variants found in the IDH1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-208237088-G-C | not specified | Likely benign (Feb 12, 2022) | ||
2-208237091-C-T | not specified | Likely benign (Apr 12, 2020) | ||
2-208237101-T-C | not specified | Uncertain significance (Feb 21, 2022) | ||
2-208237101-T-G | not specified | Uncertain significance (Dec 23, 2023) | ||
2-208237104-A-T | not specified | Uncertain significance (Jun 29, 2021) | ||
2-208237106-C-T | not specified | Likely benign (Jun 03, 2020) | ||
2-208237117-C-T | not specified | Uncertain significance (Jun 17, 2023) | ||
2-208237118-T-C | not specified | Likely benign (Jun 20, 2022) | ||
2-208237119-C-T | not specified | Uncertain significance (May 12, 2022) | ||
2-208237128-T-C | not specified | Uncertain significance (Jan 17, 2024) | ||
2-208237132-T-A | not specified | Uncertain significance (May 01, 2022) | ||
2-208237132-T-C | not specified | Uncertain significance (Mar 02, 2024) | ||
2-208237136-C-A | not specified | Uncertain significance (Jun 14, 2024) | ||
2-208237136-C-T | not specified | Likely benign (May 20, 2024) | ||
2-208237140-A-G | not specified | Uncertain significance (May 06, 2024) | ||
2-208237143-G-A | not specified | Uncertain significance (Nov 15, 2022) | ||
2-208237145-A-T | not specified | Uncertain significance (Jan 31, 2024) | ||
2-208237146-T-C | not specified | Uncertain significance (Feb 25, 2024) | ||
2-208237148-C-A | not specified | Uncertain significance (Jul 18, 2023) | ||
2-208237153-A-G | not specified | Uncertain significance (Aug 10, 2021) | ||
2-208237162-G-A | not specified | Uncertain significance (Dec 12, 2022) | ||
2-208237162-G-T | not specified | Uncertain significance (Jan 17, 2024) | ||
2-208237166-C-T | not specified | Likely benign (May 12, 2023) | ||
2-208237167-A-G | not specified | Uncertain significance (Mar 23, 2024) | ||
2-208237169-A-G | not specified | Likely benign (Aug 07, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
IDH1 | protein_coding | protein_coding | ENST00000415913 | 8 | 29848 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.62e-12 | 0.0737 | 125703 | 0 | 45 | 125748 | 0.000179 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.604 | 207 | 233 | 0.889 | 0.0000124 | 2754 |
Missense in Polyphen | 87 | 106.08 | 0.82011 | 1272 | ||
Synonymous | 0.873 | 72 | 82.1 | 0.877 | 0.00000486 | 757 |
Loss of Function | 0.404 | 19 | 21.0 | 0.905 | 0.00000109 | 248 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000492 | 0.000481 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000217 | 0.000217 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000178 | 0.000176 |
Middle Eastern | 0.000217 | 0.000217 |
South Asian | 0.000294 | 0.000294 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Disease
- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. {ECO:0000269|PubMed:19117336, ECO:0000269|PubMed:19935646}. Note=The gene represented in this entry is involved in disease pathogenesis. Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2- hydroxyglutarate are correlated with an elevated risk of malignant brain tumors. {ECO:0000269|PubMed:19935646}.; DISEASE: Note=Genetic variations are associated with cartilaginous tumors such as enchondroma or chondrosarcoma. Mutations of Arg-132 to Cys, Gly or His abolish the conversion of isocitrate to alpha- ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)- 2-hydroxyglutarate. {ECO:0000269|PubMed:26161668}.;
- Pathway
- Citrate cycle (TCA cycle) - Homo sapiens (human);Central carbon metabolism in cancer - Homo sapiens (human);Glutathione metabolism - Homo sapiens (human);Peroxisome - Homo sapiens (human);Warburg Effect;The oncogenic action of Succinate;The oncogenic action of Fumarate;The oncogenic action of 2-hydroxyglutarate;The oncogenic action of L-2-hydroxyglutarate in Hydroxygluaricaciduria;The oncogenic action of D-2-hydroxyglutarate in Hydroxygluaricaciduria ;Glutathione metabolism;miR-targeted genes in epithelium - TarBase;miR-targeted genes in leukocytes - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in squamous cell - TarBase;TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc);Amino Acid metabolism;Neutrophil degranulation;Disease;Metabolism of proteins;Innate Immune System;Immune System;Metabolism;Peroxisomal protein import;NADPH regeneration;Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate;Diseases of metabolism;Metabolism of cofactors;Metabolism of vitamins and cofactors;TCA cycle
(Consensus)
Recessive Scores
- pRec
- 0.416
Intolerance Scores
- loftool
- 0.568
- rvis_EVS
- 0.02
- rvis_percentile_EVS
- 55.45
Haploinsufficiency Scores
- pHI
- 0.864
- hipred
- Y
- hipred_score
- 0.507
- ghis
- 0.456
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.915
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Idh1
- Phenotype
- homeostasis/metabolism phenotype; growth/size/body region phenotype; respiratory system phenotype; immune system phenotype; skeleton phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Zebrafish Information Network
- Gene name
- idh1
- Affected structure
- whole organism
- Phenotype tag
- abnormal
- Phenotype quality
- has fewer parts of type
Gene ontology
- Biological process
- glyoxylate cycle;tricarboxylic acid cycle;isocitrate metabolic process;2-oxoglutarate metabolic process;protein targeting to peroxisome;NADP metabolic process;NADPH regeneration;glutathione metabolic process;response to oxidative stress;female gonad development;neutrophil degranulation;response to steroid hormone;regulation of phospholipid catabolic process;regulation of phospholipid biosynthetic process
- Cellular component
- extracellular region;cytoplasm;mitochondrion;peroxisome;peroxisomal matrix;cytosol;secretory granule lumen;extracellular exosome;tertiary granule lumen;ficolin-1-rich granule lumen
- Molecular function
- magnesium ion binding;isocitrate dehydrogenase (NADP+) activity;signaling receptor binding;identical protein binding;protein homodimerization activity;cadherin binding;NADP binding;NAD binding;(R)-2-hydroxyglutarate dehydrogenase activity